We are leveraging the principle of synthetic lethality to develop medicines that take direct aim at specific tumors. Using an approach that starts and ends with patients, we’re expanding the reach of genetically targeted therapies.

In Memoriam
José Baselga
José Baselga

The world has lost a very special person with the death of one of our scientific founders, José Baselga. Every loss is a tragedy, but this loss is a huge one felt around the world not only by his family and friends but also by the many, many people who worked with him, the thousands of breast cancer patients he cared for and the millions of people touched by the drugs he helped develop.

José has been part of Tango since our inception and played a very important role advising us as we have grown. He had a truly larger-than-life personality and boundless energy, and was a wonderful person who loved his family, FC Barcelona and doing everything he could to bring research advances to patients as fast as humanly possible. He had so much more to give.

In addition to being a trusted advisor, José was a valued friend, and I will miss him deeply. We will honor him going forward by bringing what we do scientifically to patients as fast as we possibly can and always putting them first in everything we do.

Barbara Weber
President and CEO